← Leaderboards
Yukai He
Augusta University
$5,488,619
Attributed
$5,488,619
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $486K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,488,619 · 4
By mechanism
R01$4,946,589 · 3
K01$542,030 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dendritic Cells”
- Barton F Haynes · Duke University$112,608,041
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
- James C. Paulson · Scripps Research Institute$41,568,802
- Ulrich H Von Andrian · Harvard Medical School$32,521,007
- Donald L Morton · John Wayne Cancer Institute$29,042,629
Research focus
Dendritic CellsEpitopesResponseAntigensTumorCellsT-LymphocyteCd8b1 GeneMalignant NeoplasmsVaccinesEngineeringImmunizationImmunotherapyIn VitroFutureIn VivoCessation Of LifeCancer EtiologyIncidenceImmune SystemMalignant Neoplasm Of LiverExcisionGenerationsHepatocyte
Grant awards (22)
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$325,779
R01 · FY2024 · CA · contact PI
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$365,377
R01 · FY2023 · CA · contact PI
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$365,377
R01 · FY2022 · CA · contact PI
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$29,909
R01 · FY2021 · CA · contact PI
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$370,716
R01 · FY2020 · CA · contact PI
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma$485,965
R01 · FY2019 · CA · contact PI
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines$320,588
R01 · FY2018 · CA · contact PI
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines$320,588
R01 · FY2017 · CA · contact PI
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines$320,588
R01 · FY2016 · CA · contact PI
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines$319,966
R01 · FY2015 · CA · contact PI
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines$330,765
R01 · FY2014 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$270,921
R01 · FY2011 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$279,300
R01 · FY2010 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$279,300
R01 · FY2009 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$279,300
R01 · FY2008 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$247,003
R01 · FY2007 · CA · contact PI
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization$35,147
R01 · FY2007 · CA · contact PI
Regulation of Antitumor Immunity by DC Subsets$114,909
K01 · FY2006 · AR · contact PI
Regulation of Antitumor Immunity by DC Subsets$111,561
K01 · FY2005 · AR
Regulation of Antitumor Immunity by DC Subsets$108,311
K01 · FY2004 · AR
Regulation of Antitumor Immunity by DC Subsets$105,156
K01 · FY2003 · AR
Regulation of Antitumor Immunity by DC Subsets$102,093
K01 · FY2002 · AR